Compare Biogen Inc (BIIB) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs ProShares UltraPro S&P500 — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while ProShares UltraPro S&P500 trades at $154.39. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | UPRO | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $155.10 |
52-Week Low | $128.93 | $89.29 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
UPRO trades at $154.55, down 0.28% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF shows strong institutional interest with Bay Colony Advisors establishing a new position. Market sentiment is mixed as the S&P 500 faces valuation concerns at record highs, with the Fear & Greed index indicating greed zone conditions amid inflation data anticipation.
The leveraged ETF's performance remains tied to S&P 500 momentum, with technical support at $150-$152 providing downside protection. Key risks include market volatility and overbought conditions, while institutional accumulation suggests confidence in near-term upside potential despite broader market valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
